-
公开(公告)号：US11654162B2
公开(公告)日：2023-05-23
申请号：US16948507
申请日：2020-09-21
Applicant: NORTHERN THERAPEUTICS, INC.
Inventor： Duncan John Stewart
CPC classification number: A61K35/36 , A61K35/12 , A61K38/1858 , A61K48/005 , A61K48/0008 , C12N5/0656 , C12N5/0691 , A61K35/28 , A61K35/33 , C12N2510/02
Abstract: Cell based therapy comprises administration to the lung by injection into the blood system of viable, mammalian cells effective for alleviating or inhibiting pulmonary disorders. The cells may express a therapeutic transgene or the cells may be therapeutic in their own right by inducing regenerative effects.
-
公开(公告)号：US20180333438A1
公开(公告)日：2018-11-22
申请号：US15806539
申请日：2017-11-08
Applicant: Northern Therapeutics Inc.
Inventor： Duncan John Stewart
CPC classification number: A61K35/36 , A61K35/12 , A61K38/1858 , A61K48/0008 , A61K48/005 , C12N5/0656 , C12N5/0691 , C12N2510/02
Abstract: Cell based therapy comprises administration to the lung by injection into the blood system of viable, mammalian cells effective for alleviating or inhibiting pulmonary disorders. The cells may express a therapeutic transgene or the cells may be therapeutic in their own right by inducing regenerative effects.
-
公开(公告)号：US10828336B2
公开(公告)日：2020-11-10
申请号：US15443789
申请日：2017-02-27
Applicant: NORTHERN THERAPEUTICS, INC.
Inventor： Duncan John Stewart
Abstract: Cell based therapy comprises administration to the lung by injection into the blood system of viable, mammalian cells effective for alleviating or inhibiting pulmonary disorders. The cells may express a therapeutic transgene or the cells may be therapeutic in their own right by inducing regenerative effects.
-
公开(公告)号：US20210145894A1
公开(公告)日：2021-05-20
申请号：US16948507
申请日：2020-09-21
Applicant: NORTHERN THERAPEUTICS, INC.
Inventor： DUNCAN JOHN STEWART
Abstract: Cell based therapy comprises administration to the lung by injection into the blood system of viable, mammalian cells effective for alleviating or inhibiting pulmonary disorders. The cells may express a therapeutic transgene or the cells may be therapeutic in their own right by inducing regenerative effects.
-
公开(公告)号：US10660922B2
公开(公告)日：2020-05-26
申请号：US15806539
申请日：2017-11-08
Applicant: Northern Therapeutics Inc.
Inventor： Duncan John Stewart
Abstract: Cell based therapy comprises administration to the lung by injection into the blood system of viable, mammalian cells effective for alleviating or inhibiting pulmonary disorders. The cells may express a therapeutic transgene or the cells may be therapeutic in their own right by inducing regenerative effects.
-
Patent Agency Ranking
公开(公告)号：US09827270B2
公开(公告)日：2017-11-28
申请号：US14303748
申请日：2014-06-13
Applicant: Northern Therapeutics, Inc.
Inventor： Duncan John Stewart
CPC classification number: A61K35/36 , A61K35/12 , A61K38/1858 , A61K48/0008 , A61K48/005 , C12N5/0656 , C12N5/0691 , C12N2510/02
Abstract: Cell based therapy comprises administration to the lung by injection into the blood system of viable, mammalian cells effective for alleviating or inhibiting pulmonary disorders. The cells may express a therapeutic transgene or the cells may be therapeutic in their own right by inducing regenerative effects.
-
7.发明申请METHODS OF DIAGNOSING, PREVENTING, AND TREATING EARLY ONSET OF PULMONARY HYPERTENSION 审中-公开诊断，预防和治疗早期高血压的方法
公开(公告)号：WO2004058293A1
公开(公告)日：2004-07-15
申请号：PCT/CA2003/002007
申请日：2003-12-24
Applicant: NORTHERN THERAPEUTICS INC. , STEWART, Duncan, J. , BABAEI, Saeid , COURTMAN, David
Inventor： STEWART, Duncan, J. , BABAEI, Saeid , COURTMAN, David
IPC: A61K38/18
CPC classification number: A61K31/216 , A61K31/198 , A61K38/06 , A61K38/1866 , A61K38/1891 , A61K38/44 , A61K48/005 , C12Y114/13039
Abstract: Early onset of pulmonary disorders such as pulmonary hypertension are treated or prevented by administration of an apoptosis inhibitor or a survival factor. Early onset of such disorders may be diagnosed by assessing apoptosis in lung tissue.
Abstract translation: 通过施用凋亡抑制剂或存活因子来治疗或预防肺部疾病如肺动脉高压的早期发作。 可以通过评估肺组织中的细胞凋亡来诊断此类疾病的早期发作。
-
公开(公告)号：WO2023023846A1
公开(公告)日：2023-03-02
申请号：PCT/CA2022/051267
申请日：2022-08-22
Applicant: NORTHERN THERAPEUTICS, INC.
Inventor： STEWART, Duncan , COURTMAN, David
IPC: C12N15/113 , A61K35/12 , A61K38/44 , A61K48/00 , A61P9/00 , A61P9/10 , C12N9/02 , C12N15/10 , C12N15/53 , C12N15/85
Abstract: Nucleic acid molecules comprising truncated forms of the human cytomegalovirus (CMV) promoter are operably linked to a transgene of interest, including those encoding eNOS protein are taught. Vectors comprising these nucleic acid molecules and host cells transformed by these vectors and methods of producing cellular compositions are used for the treatment of a variety of pulmonary and cardiac diseases. There is provided a truncated human cytomegalovirus (CMV) enhancer element comprising SEQ ID NO: 1 or a functional derivative thereof. A truncated human cytomegalovirus (CMV) promoter comprising the truncated CMV enhancer element is taught. A polynucleotide expression cassette comprising the truncated CMV promoter and a transcribable polynucleotide operably linked to the truncated CMV promoter polynucleotide construct, a host cell comprising the polynucleotide expression cassette, and use of the host cell treat renal, vascular, pulmonary, or cardiac disease in the patient are taught.
-
公开(公告)号：IL192893A
公开(公告)日：2014-03-31
申请号：IL19289308
申请日：2008-07-17
Applicant: STEWART DUNCAN , NORTHERN THERAPEUTICS INC , AN GO GEN INC
Inventor： STEWART DUNCAN
-
公开(公告)号：ES2546937T3
公开(公告)日：2015-09-30
申请号：ES07009031
申请日：1999-09-23
Applicant: NORTHERN THERAPEUTICS INC
Inventor： STEWART DUNCAN J
IPC: A61K35/36 , A61K35/28 , A61K35/33 , A61K38/18 , A61K38/44 , A61K48/00 , A61P9/12 , A61P11/00 , C07K14/52 , C12N5/10 , C12N15/09
Abstract: Uso de células de mamífero transfectadas, viables, seleccionadas de fibroblastos y células endoteliales, conteniendo dichas células de mamífero transfectadas al menos un transgen expresable que codifica un factor angiogénico o vasoactivo para la preparación de una composición farmacéutica para aliviar un trastorno pulmonar en un paciente o síntomas del mismo, en donde dicha composición farmacéutica se ha de administrar a la circulación pulmonar de un paciente mamífero.
-
-
-
-
-
-
-
-
-
Search Results
16
records
(took 0.025 seconds)
